Related trials
Lopaciuk, 3000 - subcutaneous heparin vs intravenous heparin
RE-COVER, 2009 - dabigatran vs vitamin K antagonists
Romera, 2009 - Tinzaparin vs acenocoumarol
Gonz�lez-Fajardo, 2008 - Enoxaparin vs coumarin
Botticelli DVT, 2008 - apixaban vs heparin/VKA
Einstein-DVT Dose-Ranging Study, 2008 - rivaroxaban vs heparin/VKA
VanGogh DVT, 2007 - idraparinux vs heparin/VKA
VanGogh PE, 2007 - idraparinux vs heparin/VKA
Daskalopoulos, 2005 - LMWH at home vs UFH in hospital
Fiessinger , 2005 - ximelagatran vs vitamin K antagonists
Chong, 2005 - LMWH at home vs UFH in hospital
Kearon, 2004 - 4 months vs 3 months
Ramacciotti, 2004 - LMWH at home vs UFH in hospital
MATISSE, 2004 - fondaparinux vs enoxaparin
Lee, 2003 - Dalteparin vs warfarin
Agnelli, 2003 - 6-12 months vs 3 months
Kakkar, 2003 - Bemiparin vs warfarin
Deitcher, 2003 - Enoxaparin vs warfarin
MATISSE PE, 2003 - fondaparinux vs heparin/VKA
Hull, 2002 - Tinzaparin vs warfarin
Meyer, 2002 - Enoxaparin vs warfarin
Agnelli, 2001 - 12 months vs 3 months
Merli (once daily vs UFH), 2001 - once daily enoxaparin vs UFH
Lopez-Beret, 2001 - Nadroparin vs acenocoumarol
Merli, 2001 - once daily enoxaparin vs twice daily enoxaparin
See also:
All venous thrombosis clinical trials
|
|
Treatments
Studied treatment |
Long course of therapy (6 months for proximal DVT and/or PE; 12 weeks for calf DVT) by fluindione adjusted for INR range of 2.0 to 3.0
|
Control treatment |
Short oral anticoagulant course (3 months for proximal DVT and/or PE; 6 weeks for isolated calf
DVT) by fluindione adjusted for INR range of 2.0 to 3.0
|
Remarks |
randomization at the end of heparin therapy |
Patients
Inclusion criteria |
symptomatic thrombus below
popliteal vein or proximal deep vein thrombosis and/or pulmonary embolism confirmed by positive
Doppler ultrasonography or venography |
Exclusion criteria |
Pregnancy, breast feeding, previous venous thromboembolism, vena cava filter implantation, surgical thrombectomy, free-floating thrombus in the inferior vena cava lumen, deep vein thrombosis or pulmonary embolism whose diagnosis did not fulfill the predefined criteria, evolutionary cancer or malignant hematological disease, known biological thrombophilia, severe pulmonary embolism, pulmonary embolism treated by thrombolysis, myocardiopathy or other diseases justifying prolonged anticoagulation therapy, and liver insufficiency |
Baseline characteristics |
time of randomization |
after heparin therapy |
|
Method and design
Randomized effectives |
NA / NA (studied vs. control) |
Design |
Parallel groups |
Blinding |
open |
Follow-up duration |
15 months after randomization� |
Lost to follow-up |
n=22 |
Number of centre |
94 |
Geographic area |
France |
Primary endpoint |
Recurrent VTE |
Results
No results available for this trial
- no clinical endpoint reported
Reference(s)
-
Pinede L, Ninet J, Duhaut P, Chabaud S, Demolombe-Rague S, Durieu I, Nony P, Sanson C, Boissel JP.
Comparison of 3 and 6 months of oral anticoagulant therapy after a first episode of proximal deep vein thrombosis or pulmonary embolism and comparison of 6 and 12 weeks of therapy after isolated calf deep vein thrombosis..
Circulation 2001;103:2453-60
Pubmed
|
Hubmed
| Fulltext
|